This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Should You Invest in the iShares U.S. Healthcare ETF (IYH)?
by Zacks Equity Research
Sector ETF report for IYH
Big Pharma Stocks Dive Amid Trade War Jitters & Inflation Woes
by Sundeep Ganoria
Shares of pharma giants like PFE, J&J, AZN, MRK and ABBV decline on investor concerns that retaliatory tariffs could drive up drug prices for U.S. consumers.
Pharma Stock Roundup: FDA Nod to SNY, AZN & NVS, JNJ Talc Suits Failure
by Kinjel Shah
FDA approves SNY's hemophilia therapy, fitusiran, and NVS' rare kidney disease drug, Vanrafia.
The Zacks Analyst Blog Highlights Johnson & Johnson and Pfizer
by Zacks Equity Research
Johnson & Johnson and Pfizer are part of the Zacks top Analyst Blog
JNJ vs. PFE: Which Drug Giant is a Better Buy Now?
by Kinjel Shah
Both JNJ & PFE expect their sales and profits to improve in 2025.
Johnson & Johnson (JNJ) Exceeds Market Returns: Some Facts to Consider
by Zacks Equity Research
The latest trading day saw Johnson & Johnson (JNJ) settling at $155.36, representing a +1.38% change from its previous close.
PFE, MRK, LLY & Other Drug Stocks Down Amid Tariff Jitters
by Kinjel Shah
Stocks of PFE, MRK, ABBV, LLY and others declined on Tuesday due to uncertainty surrounding Trump's proposed tariffs on pharma imports.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
by Zacks Equity Research
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Stock Market News For Apr 2, 2025
by Zacks Equity Research
Wall Street closed mixed on Tuesday to finish the first trading day of second-quarter 2025 after a choppy session.
Can Johnson & Johnson (JNJ) Keep the Earnings Surprise Streak Alive?
by Zacks Equity Research
Johnson & Johnson (JNJ) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
J&J's Third Bankruptcy Attempt to End Talc Suits Rejected
by Zacks Equity Research
J&J fails in its third attempt to settle tens of thousands of lawsuits claiming its talc-based powder caused cancer.
Are You Looking for a High-Growth Dividend Stock?
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes? Let's find out.
JNJ's Rybrevant-Lazcluze Combo Outshines AZN's Tagrisso in Lung Cancer
by Zacks Equity Research
Study investigators expect that J&J's combo drug can extend overall survival by at least a year over the current standard of care in certain NSCLC patients.
RDY & Bio-Thera Ink Deal for JNJ's Stelara/Simponi Biosimilar
by Zacks Equity Research
Dr. Reddy's inks collaboration deal with Bio-Thera to develop and commercialize proposed biosimilar candidates of J&J's Stelara and Simponi in Southeast Asia.
Investors Heavily Search Johnson & Johnson (JNJ): Here is What You Need to Know
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Johnson & Johnson (JNJ). This makes it worthwhile to examine what the stock has in store.
Here's Why Johnson & Johnson (JNJ) is a Strong Value Stock
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
by Zacks Equity Research
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Should First Trust Dow 30 Equal Weight ETF (EDOW) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for EDOW
Johnson & Johnson (JNJ) Stock Dips While Market Gains: Key Facts
by Zacks Equity Research
The latest trading day saw Johnson & Johnson (JNJ) settling at $163.29, representing a -0.21% change from its previous close.
ACIU Stock Crashes 18.3% in a Month: Buy, Sell or Hold?
by Ekta Bagri
AC Immune's shares decline 18.3% in a month. While the company's pipeline progress is encouraging, we advise investors to remain on the sidelines for now.
Take the Zacks Approach to Beat the Markets: CMS Energy, Chevron, AutoZone in Focus
by Santanu Roy
Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.
Here's How to Play JNJ Stock as it Announces $55B US Investment Plan
by Kinjel Shah
Those who own JNJ stock may stay invested for some time, as the company is optimistic about a better performance in 2025.
J&J to Invest $55B in United States to Boost Manufacturing, R&D
by Zacks Equity Research
JNJ announces plans to invest more than $55 billion over the next four years to expand its manufacturing footprint in the United States.
Pharma Stock Roundup: PFE's Final Haleon Stake Sale, AZN, SNY M&A Deals
by Kinjel Shah
Pfizer sells 7.3% remaining stake in Haleon. FDA approves the expanded use of JNJ and NVS drugs.
J&J's Tremfya Gets FDA Nod for 2nd IBD Condition Crohn's Disease
by Zacks Equity Research
FDA approves J&J's Tremfya for its fourth indication and the second IBD condition.